1	
2	Dynamic interactions of influenza viruses in Hong Kong during
3	1998-2018
4	
5	Wan Yang ^{1*} , Eric H. Y. Lau ² , Benjamin J. Cowling ²
6	¹ Department of Epidemiology, Mailman School of Public Health, Columbia University, New
7	York, NY 10032
8	² WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public
9	Health, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong Special
10	Administrative Region, China
11	
12	
13	*Correspondence to:
14	Wan Yang
15	Department of Epidemiology
16	Mailman School of Public Health
17	Columbia University
18	722 W 168th Street, Room 514, New York, NY 10032
19	Phone: (212) 305-0421
20	Email: wy2202@columbia.edu

21 Abstract

22 Influenza epidemics cause substantial morbidity and mortality every year worldwide. 23 Currently, two influenza A subtypes, A(H1N1) and A(H3N2), and type B viruses co-circulate 24 in humans and infection with one type/subtype could provide cross-protection against the 25 others. However, it remains unclear how such ecologic competition via cross-immunity and 26 antigenic mutations that allow immune escape impact influenza epidemic dynamics at the 27 population level. Here we develop a comprehensive model-inference system and apply it to 28 study the evolutionary and epidemiological dynamics of the three influenza types/subtypes 29 in Hong Kong, a city of global public health significance for influenza epidemic and 30 pandemic control. Utilizing long-term influenza surveillance data since 1998, we are able to 31 estimate the strength of cross-immunity between each virus-pairs, the timing and 32 frequency of punctuated changes in population immunity in response to antigenic 33 mutations in influenza viruses, and key epidemiological parameters over the last 20 years 34 including the 2009 pandemic. We find evidence of cross-immunity in all types/subtypes, 35 with strongest cross-immunity from A(H1N1) against A(H3N2). Our results also suggest 36 that A(H3N2) may undergo antigenic mutations in both summers and winters and thus 37 monitoring the virus in both seasons may be important for vaccine development. Overall, our study reveals intricate epidemiological interactions and underscores the importance of 38 39 simultaneous monitoring of population immunity, incidence rates, and viral genetic and 40 antigenic changes.

41

42 Key words: Influenza; cross-immunity; ecologic competition; seasonality; population
43 susceptibility; punctuated antigenic change

44 Introduction

45 Influenza epidemics recur annually in many regions of the world and cause significant 46 morbidity and mortality, leading to 3 to 5 million severe infections and 291,000 to 646,000 47 deaths worldwide each year (1, 2). These recurrent epidemics are a combined outcome of 48 viral antigenic changes, interactions among co-circulating influenza viruses, transmission 49 and host immune response. Influenza viruses undergo continual genetic mutations and 50 punctuated antigenic changes, which allow them to escape prior immunity and cause new 51 epidemics (3-6). In addition, currently two influenza A subtypes, A(H1N1) and A(H3N2), 52 and influenza B co-circulate in humans; and infection of a certain type/subtype can result 53 in partial immunity to influenza strains of the same type/subtype as well as strains across 54 subtypes (7-15) and types (16-18). The latter cross-reactive immunity—termed crossimmunity—leads to epidemiological interactions among influenza viruses that, along with 55 56 viral antigenic changes, shape influenza phylodynamics and epidemic dynamics (19-31). Improving understanding of interactions among influenza viruses and the resulting impact 57 58 on epidemic dynamics will thus provide insights to aid public health efforts to mitigate the 59 burden of influenza.

60

As observed epidemic dynamics are the result of the aforementioned key
evolutionary and epidemiological processes, in this study, we utilized a long-term influenza
incidence surveillance dataset collected in Hong Kong since 1998 to estimate the timing of
punctuated antigenic changes, strength of cross-immunity, duration of immunity, as well as
other key epidemiological parameters for each of the three types/subtypes. Hong Kong is a
subtropical city located in Southeast Asia. Unlike the highly seasonal epidemics in

temperate regions, in the subtropics and tropics, influenza epidemics can occur at any time
of the year (32, 33) and, often, multiple types/subtypes co-circulate causing co-epidemics
of comparable magnitude. The long-term Hong Kong dataset with diverse epidemics thus
provides a unique opportunity to study the interplay of different influenza types/subtypes
at the population level.

72

73 These highly diverse epidemic dynamics, however, also present major challenges 74 for inference on transmission dynamics. In an exploratory analysis, we coupled a 75 commonly used multi-strain susceptible-infected-recovered-susceptible (SIRS) model (24) 76 with a particle filter (34-36), a Bayesian inference method, and applied it to the Hong Kong 77 dataset. While this model-inference system was able to reproduce the observed epidemic 78 pattern, the model state did not appear to converge (see Fig. S1). Three major challenges 79 exist. First, the seasonality of influenza in part shapes the epidemic dynamics and thus 80 should be accounted for in the model. However, unlike the winter-time epidemics in 81 temperate regions that have been well-characterized by seasonal forcing of climate 82 variables (humidity alone or with temperature) (37, 38), to date no models capable of 83 capturing the diverse seasonal pattern in tropical and subtropical climates exist. Second, to estimate epidemiological parameters such as the duration of immunity, the inference 84 85 system must be able to preserve such long-term epidemic features. Single-pass filters (e.g., the particle filter) did not appear to do so as seen in our exploratory analysis. Multi-pass 86 filters (e.g., iterated filters (39-41)) have such built-in capability, however, are less adept in 87 88 modeling diverse epidemic dynamics (42). Finally, it is challenging to estimate a large 89 number of parameters needed to characterize the interactions between virus-pairs.

90

We therefore developed a model-inference system that addresses the above 91 92 challenges. The basic reproductive number R_0 is a key epidemiological parameter 93 describing the transmissibility of an infection, defined as the average number of secondary 94 infections that arise from a primary infection in a naïve population. We thus first estimate, 95 for each influenza type/subtype, the average R_0 in each week of the year based on the 96 average annual epidemic cycle, i.e. the empirical seasonal cycle. We then incorporate this 97 R_0 seasonal cycle (as the prior distribution) in the model-inference system to control for 98 the seasonality observed in Hong Kong. For the second challenge, we combine the IF2 99 iterated filtering algorithm (41) with space re-probing (36, 43), a technique that allows 100 continuous exploring of state space. The combined SR-IF2 inference method coupled with 101 the empirical seasonal multi-strain SIRS model is thus able to preserve the long-term 102 epidemic feature while adeptly explore the state space to capture the epidemic dynamics. 103 To estimate parameters in high dimensional state space, we take a multi-round inference 104 strategy; in the first round, we parse the entire state space into subspaces and test each to 105 find the optimal subspace: subsequent rounds then build on the previous one until the 106 model estimates converge. Indeed, testing using model-generated mock epidemics 107 indicates that this model-inference system and optimization strategy is able to recover the 108 true model state variables and parameters (*SI Appendix* and Figs S2 and S3).

109

Here we apply the validated model-inference system to the Hong Kong dataset and
infer how major antigenic evolutions and cross-immunity affect influenza transmission
dynamics therein over the last 20 years. Our results reveal intricate ecological interactions

among the three co-circulating influenza types/subtypes and their impacts on long-terminfluenza epidemic dynamics.

115

116 **Results**

117 **Overall influenza epidemic characteristics and seasonal cycles in Hong Kong.** During 118 Jan 1998—July 2018 (~20 years), there were 17 A(H1N1), 21 A(H3N2), and 18 B 119 epidemics, respectively (or 13, 19 and 14, respectively, if only counting larger epidemics; 120 see *SI Appendix* and Figs. S4 and S5 for divisions of individual epidemics). Figure 1 shows 121 the superimposed annual cycle for each influenza type/subtype in Hong Kong during the 122 study period and the average cycle excluding 2009 for the A(H1N1) pandemic in that year. 123 All three types/subtypes were able to circulate any time in the year. Epidemics of A(H1N1) 124 and A(H3N2) occurred in both winter and summer with similar magnitudes (Fig 1 A and 125 B). In comparison, for influenza B, major epidemics tended to occur in winter months (Fig 126 1C). As a result, the estimated R_{θ} seasonal cycle has clear bimodal peaks for the two A 127 subtypes (Fig 1 D and E), although to a less extent for A(H1N1); and for type B, it has only 128 one peak in the winter.

129

Model-fits to influenza epidemic dynamics in Hong Kong (1998–2018). Figure 2 shows
the model-fits to the epidemic curves of the three influenza types/subtypes. Despite the
highly irregular epidemic timing and intensity, the model-inference system, run
continuously through the entire 20-year study period, was able to recreate the observed
epidemic dynamics for all three types/subtypes. Distributions of residuals were centered at
0, indicating no systematic biases of the model (Fig S6). In addition, the model-inference

136	system was able to accurately estimate the infection rates during both epidemic and non-
137	epidemic periods for all types/subtypes. In particular, over the 20-year study period,
138	epidemics of A(H1N1) were less frequent compared to the other two types/subtypes. For
139	instance, few A(H1N1) cases were reported during Jan 1998 – Dec 1999 (the entire 2-year
140	period) and May 2002 – Dec 2004 (the entire 2.5-year period). While R_0 followed the same
141	seasonal cycle as years with epidemics (Fig 3A), the estimated infection rates remained at
142	near-zero over these extended time-periods when A(H1N1) was not in circulation (Fig 2A)

143

144 In addition to running the model continuously without re-initiation to correct for 145 model errors, we included a continuous seeding at a constant rate of 1 case per 100,000 146 population per 10 days for all types/subtypes. This epidemic seeding represents travel-147 related importation of cases into local population, since Hong Kong is a transportation hub 148 highly connected to places worldwide. This seeding is also designed to test the accuracy of 149 estimates of key model state variables and parameters, as they are intricately linked to the 150 infection rate. Foremost, overestimation of population susceptibility would lead to 151 overestimation of cases during non-epidemic periods, as the seeded cases would lead to an 152 epidemic should the effective reproductive number R_e (computed as R_0 times population 153 susceptibility) be above unity and sustain so. Conversely, underestimation of susceptibility 154 would lead to underestimation of cases during epidemic periods or require unrealistically 155 frequent antigenic changes prior to an epidemic. Further, population susceptibility is also 156 linked to the duration of immunity and the strength of cross-immunity. Loss of immunity 157 (determined by the immunity period) replenishes the susceptible pool whereas gaining of 158 cross-immunity from infection by other types/subtypes (determined by the strength of

159	cross-immunity) can reduce susceptibility. As such, estimates of these related parameters
160	should also be accurate in order to achieve accurate estimation of infection rate. Taken
161	together, the accurate infection rate estimates suggest that the model-inference system was
162	also able to accurately estimate key state variable variables and parameters.
163	
164	Population susceptibility, <i>R</i>₀, infectious period, and immunity period. Table 1
165	summarizes the estimates of key epidemiological parameters for each influenza (sub)type.
166	Weekly estimates are shown in Fig 2 (susceptibility), Fig 3 (R_0 and R_e), and Fig S7
167	(infectious period, immunity period, and cross-immunity). During Jan 1998 – July 2018,
168	estimated population susceptibility was higher for A(H1N1) and B than A(H3N2) (Fig 2).
169	The mean levels and ranges were 66.6% (range: 50.9–90.3%) for A(H1N1), 60.8% (46.4–
170	89.0%) for A(H3N2), and 68.6% (50.6–87.8%) for B, respectively. These estimates were
171	consistent with the relative infection rates of individual types/subtypes. Note, however,
172	due to stringent public health interventions (i.e., case isolation, contact tracing, and school
173	closure) implemented from early May to mid-July 2009 (44) and self-protection (e.g.,
174	improved personal hygiene and social distancing) during that time (45), the pandemic in
175	Hong Kong unfolded relatively slowly and estimated population susceptibility at the
176	beginning of the 2009 pandemic was relatively low (\sim 71% in mid-July; Fig 2).
177	
178	The basic reproductive number R_{θ} was in general higher for A(H3N2) (1.6; range:
179	1.3–2.0) than A(H1N1) (1.4; 1.1–1.8) and B (1.4; 1.1–1.8). Estimated R_0 for the A(H1N1)
180	pandemic in mid-July 2009 was 1.5 (95% CI: 1.3, 1.8), similar to previous estimates (46).
181	The mean effective reproductive number R_e , while fluctuated over time (Fig 3B), did

182	average to unity over the 20-year study period for all types/subtypes. The estimated
183	infectious period was slightly longer for A(H3N2) (3.0; 2.6–4.3 days) and B (3.1; 2.2–4.1
184	days) than A(H1N1) (2.6; 2.2–3.8 days).
185	
186	The length of immunity period determines the duration of immune protection from
187	prior infection and is thus a key epidemiological parameter shaping the long-term
188	dynamics of influenza epidemics. However, it remains difficult to estimate due to the
189	complex nature of immunogenicity and lack of detail, longitudinal serological data (47, 48).
190	Given the uncertainty, we tested a wide prior range from 1 to 9 years. The posterior
191	estimate of immunity period (Table 1 and Fig S7) was about 3 years for both A(H1N1) (3.1;
192	2.6–4.0 years) and B (3.1; 2.7–3.5 years), and shorter for A(H3N2) (2.2; 1.8–2.6 years).
193	These estimates accounted for cross-immunity from infections of other types/subtypes, for
194	which, after conversion based on the strength of cross-immunity, was treated the same as
195	specific-immunity from the same type/subtype (see Eqn 1 in Methods).
196	
197	Key ecological interactions via cross-immunity. The strength of cross-immunity may
198	modulate the ecological completion among co-circulating influenza viruses. Here we
199	estimated the pair-wise cross-immunity strength, relative to specific-immunity from the
200	same type/subtype (Table 1 and Fig S7; c_{ij} denotes cross-immunity against virus- <i>i</i> gained
201	from infection of virus-j). Three interesting features seem to characterize the interactions
202	between the three influenza types/subtypes. First, interactions are asymmetric (i.e., $c_{ij} \neq c_{ji}$)
203	and cross-immunity appears to be weaker from types/subtypes with higher mutation
204	rates. In particular, among all virus-pairs, cross-immunity was the weakest when gained

205	from infection of A(H3N2) (the mean was 17% of the strength of specific-immunity against
206	A(H1N1) and 11% against B). Second, as expected, homotypic- is stronger than heterotypic
207	cross-immunity. Among all virus-pairs, cross-immunity from A(H1N1) against A(H3N2)
208	was the strongest (40%; 23–56%). Third, cross-immunity appears to mediate ecologic
209	competition among the three influenza types/subtypes, with B "controlling" A(H1N1) and
210	the latter further "controlling" A(H3N2). Specifically, the second strongest cross-immunity
211	was from B against A(H1N1) (32%; 26–40%); this, along with the strong cross-immunity
212	from A(H1N1) against A(H3N2), formed a control cascade of B \rightarrow A(H1N1) \rightarrow A(H3N2). The
213	higher mutation rate of A(H3N2) virus (4) then allowed it to escape prior immunity
214	including cross-reactive ones from A(H1N1) and B. On the other hand, cross-immunity
215	from A(H1N1) against B (23%; 19–32%) was comparable to the reverse, allowing the two
216	viruses to maintain a more balanced bidirectional ecologic competition.
217	

218 As our estimates that cross-immunity from A(H1N1) against A(H3N2) is stronger 219 than the reverse appeared to contradict previous notion that A(H3N2) outcompetes 220 A(H1N1) (see, e.g., (49)), we further used model-simulation to test the long-term impact of 221 cross-immunity under three different scenarios: 1) As estimated here, i.e., setting all cross-222 immunity terms to the posterior mean estimates; 2) A(H3N2) outcompeting A(H1N1) via 223 stronger cross-immunity, for which we set $c_{H1 \leftarrow H3}$ to 0.5 (vs. 0.4 for $c_{H3 \leftarrow H1}$); and 3) No 224 interactions, i.e., setting all cross-immunity terms to 0 (see details in SI Appendix and 225 simulated epidemics in Figs. S8-10). As shown in Fig. S11, scenario 1 most closely 226 reproduced the observed pattern of co-circulation. In contrast, scenario 2 (i.e., A(H3N2) 227 outcompeting A(H1N1)) largely underestimated the frequency of A(H1N1) epidemics,

whereas scenario 3 (i.e., no cross-immunity) largely overestimated the frequency of co-epidemics caused by multiple types/subtypes.

230

231 **Timing and frequency of punctuated antigenic changes.** Analyses of the antigenic 232 evolution of influenza have shown that major antigenic changes occur in a punctuated 233 fashion, allowing substantial increases in population susceptibility and in turn surge of 234 influenza epidemic (4, 26, 50). To capture such punctuated antigenic changes, our model-235 inference system allowed abrupt increases in population susceptibility in response to 236 unexpected epidemic surges that are potentially due to major antigenic evolutions in the influenza virus. We then used the major increases in population susceptibility (i.e., >15% 237 238 increase relative to the preceding week; results using 10% as cutoff are consistent; see 239 Table S1) to identify potential punctuated antigenic changes. Over the 20-year study 240 period, we detected such major changes in population susceptibility 7 times for A(H1N1). 241 including two due to the 2009 pandemic (Fig 2A), 12 times for A(H3N2) (Fig 2B), and 4 242 times for B (Fig 2C). Table 2 shows the estimated timing of each potential antigenic 243 innovation. Based on these estimates, punctuated antigenic changes occurred every 4.6 244 (SD=4.6; exponential distribution) years in A(H1N1) (excluding the 2009 pandemic), 1.8 (SD=1.2; gamma distribution) years in A(H3N2), and 6.2 (SD=6.2; exponential distribution) 245 246 years in B during Jan 1998 – July 2018. These results are consistent with reported 247 estimates based on antigenic testing of influenza virus isolates (4, 50). Further, interestingly, for A(H3N2), such potential antigenic innovations occurred with comparable 248 249 frequencies in both summers (7 times in May, June or July) and winters (5 times in Jan or

Feb) during the 20-year study period. In contrast, it occurred mostly in winters forA(H1N1) and only in winters for B.

252

253 **Discussion**

254 Cross-immunity among different influenza viruses has been reported and its resulting 255 potential interactions have been modeled; however, to date, its strength and impact on 256 influenza transmission dynamics at the population level remains unclear. Utilizing a long-257 term incidence surveillance dataset in Hong Kong since 1998, here we have quantified the 258 strength of cross-immunity among the two influenza A subtypes and B currently co-259 circulating in humans and the pattern of viral interactions. We have also estimated the 260 timing and frequency of punctuated surges in population susceptibility representing 261 population-level response to antigenic innovations in influenza viruses over the last 20 262 years as well as identified key variations among three influenza types/subtypes. These 263 estimates, along with other key epidemiological variable estimates including the 264 population susceptibility and basic reproductive number, provide great insight into the 265 evolutionary and epidemiological dynamics of influenza.

266

267 **Comparing transmissibility of influenza in Hong Kong and elsewhere.** Influenza 268 epidemics in subtropical Hong Kong are highly diverse and frequent (Fig1 and Figs. S4 and 269 S5). Nevertheless, R_0 estimates across all three types/subtypes are in the range of 1.1 to 270 2.0, similar to previous estimates in other regions for influenza overall (51). Few studies 271 have estimated R_0 for individual influenza types/subtypes, especially for inter-pandemic 272 seasons. Here we estimate that R_0 was similar for A(H1N1) and B (range: 1.1–1.8 for both)

273 and was slightly higher for A(H3N2) (range: 1.3–2.0). Estimated simultaneously with R_{θ} , 274 the infectious period, or generation time, was slightly longer for A(H3N2) and B than 275 A(H1N1); these estimates were very close to those based on viral shedding curves—3.0 vs 3.1 days reported for A(H3N2), 3.1 vs 3.4 days reported for B, and 2.6 vs 2.3 days reported 276 277 for A(H1N1) (52). Together, the higher transmissibility of A(H3N2) (i.e., larger R_0 and 278 longer infectious period) in part explains its larger seasonal epidemics and resulting lower 279 average population susceptibility (mean: 60.8% for A(H3N2) vs. 66.6% for A(H1N1) and 280 68.6% for B). Further, these consistent estimates indicate that our strategy using the 281 empirical R_{θ} seasonal cycle in the model-inference system is effective in controlling for the 282 elusive influenza seasonality in Hong Kong and allows for estimation of other key 283 epidemiological features. Future studies could apply the same strategy to study the diverse 284 influenza dynamics in other subtropical/tropical regions or other infections with similar 285 challenges.

286

287 **Cross-immunity and co-circulation pattern.** Multiple lines of evidence have suggested 288 cross protection offered by infection of influenza viruses of the same type/subtype as well 289 as across types/subtypes (7-18). However, some studies have reported weak or no 290 heterosubtypic and/or heterotypic cross-immunity (47, 53). As noted by authors of those 291 studies, the cross-sectional serological surveys used therein may miss the window of cross-292 immunity and/or immunity mechanisms not related to antibodies against the 293 hemagglutinin surface protein (e.g., from T cells mediated immunity). In this study, based 294 on the long-term type/subtype-specific incidence data, we estimate that there were 295 relatively strong cross-immunity against A(H3N2) by infection of A(H1N1) (~40% of the

specific-immunity) and moderate level of cross-immunity between A(H1N1) and B (2030%). Consistently, our simulations showed that interactions among the three
types/subtypes are needed to produce the pattern of co-circulation observed in Hong Kong
(Fig. S11 and Fig. S8 vs. Fig. S10).

300

301 However, our estimates of weak cross-immunities to A(H1N1) and B conferred by 302 infection of A(H3N2) appear to contradict the common notion that A(H3N2) outcompetes 303 A(H1N1) and B and, as a result, causes more frequent and larger epidemics. For instance, 304 Goldstein et al. (49) showed a negative correlation between early A(H3N2) incidence and 305 subsequent non-A(H3N2) incidence in the same season, suggesting A(H3N2) may interfere 306 with the other two types/subtypes. To test this discrepancy, we simulated epidemics under 307 both scenarios and showed that combining the frequent and large epidemics of A(H3N2) 308 with stronger cross-immunity conferred would likely drive A(H1N1) to extinction (see Fig. 309 S9; note epidemics of A(H1N1) were only possible after the imposed antigenic 310 innovations). Conversely, the strong cross-immunity from A(H1N1) against A(H3N2), as 311 estimated in this study, is consistent with the predominant circulation of A(H1N1) during 312 the 2009 pandemic despite the frequent circulation of A(H3N2) during inter-pandemic 313 seasons.

314

Thus, to understand the co-circulation pattern of influenza viruses, we need to take into account other key epidemiological features. In particular, A(H3N2) confers shorter immunity following infection and also undergoes more frequent genetic/antigenic mutations. Based on the estimated mean immunity period and implicit assumption of

319 exponential distribution in the model (Eqn 1), the mean half-life of immunity (i.e. ln2 times 320 of the mean) was 1.6 years for A(H3N2), 2.2 years for A(H1N1), and 2.1 years for B. Note 321 our estimates were shorter than reported elsewhere (e.g., 3.5 to 7 years in (47, 48)), likely 322 because, unlike those studies based on titers of antibodies against specific strains, our 323 estimates broadly applied to the entire type/subtype. Nevertheless, the relative lengths of 324 immunity period for the three influenza types/subtypes were consistent. A recent cohort-325 specific analysis (54) further showed that birth-cohorts whose first exposure was A(H1N1) 326 had long-term protection against subsequent infection by the same subtype whereas those 327 first exposed to A(H3N2) did not (See Table 4 in ref (54)). It is thus likely that A(H3N2) 328 virus' shorter/weaker immunity and more frequent mutations lead to more frequent 329 A(H3N2) epidemics, and that combining its larger epidemic size and weaker cross-330 immunity (roughly, the product of these two factors is the decrease in susceptibility to its 331 complement types/subtypes) allows the two less frequently circulating influenza 332 types/subtypes to coexist in humans.

333

334 Estimating timing and frequency of antigenic innovations based on incidence data. 335 Unlike previous analyses of genomic and/or antigenic data, here we tentatively estimate the timing and frequency of punctuated antigenic innovations based on incidence data 336 337 alone. The rationale is that punctuated antigenic innovations in influenza viruses would 338 lead to surge in population susceptibility and subsequently surge in incidence. That is, 339 incidence data encapsulate the population response to antigenic innovations and thus may 340 complement analyses of genomic and/or antigenic data (note the latter do not provide 341 information as to if an antigenic mutation would lead to an epidemic). Indeed, our results

342	are consistent with estimates from phylogenetic analyses. For instance, the two surges in
343	susceptibility to A(H1N1) during the 2009 pandemic (i.e., around 9/13/09 and 1/5/10;
344	Table 2) roughly matched with the estimated timings of amino acid mutations from
345	NextStrain (55): 1) HA1: S185T and HA2: S124N around 10/1/09 (CI: 7/26/09-1/16/10)
346	and 2) HA1: D97N round 10/30/09 (CI: 09/03/09-02/07/10). In addition, previous
347	studies estimated that punctuated antigenic innovations occur roughly every 2 to 8 years in
348	A(H3N2) (26, 50), 4 to 9 years in A(H1N1), and 3 to 14 years in B (4), based on antigenic
349	analysis of influenza virus isolates. Consistently, we estimate that antigenic innovations
350	occurred very 4.6±4.6 years in A(H1N1), every 1.8±1.2 years in A(H3N2), and every 6.2±6.2
351	years in B during Jan 1998–July 2018. These consistent results suggest incidence
352	surveillance data could be an inexpensive alternative to support detection of evolutionary
353	changes in influenza viruses, especially since these estimates reflect changes in population
354	immunity in response to antigenic innovations and thus the potential of epidemic surge.
355	
356	In addition, we note the different seasonal timing of antigenic innovations for
357	A(H3N2). While the identified antigenic innovations predominantly occurred in winters for
358	A(H1N1) and B, we find that A(H3N2) could undergo major antigenic changes in both
359	summers and winters. Further investigation is warranted, as, if confirmed, this seasonality
360	suggests that sampling A(H3N2) strains in the summer may be essential for selection of
361	vaccine strains.
362	

362

363 Our study has several limitations. First, as B lineage data were only available since
364 2014 in Hong Kong, in this study, we did not differentiate the two B lineages (i.e. Yamagata

and Victoria). Future work will extend the model-inference system to include and test the 365 366 epidemiological interactions with the two B lineages. Second, while using the empirical 367 seasonal cycle to account for the epidemic seasonality in Hong Kong has proven critical in 368 this study and may be applied to other subtropical and tropical regions with similar diverse 369 epidemics, better delineation of influenza seasonality in these climates is needed. Third, 370 we assumed that the probability of seeking medical attention for influenza is comparable to 371 other illnesses and, for simplicity, we did not consider the differences in health seeking 372 behavior among patients infected by different influenza (sub)types. Based on this 373 assumption, the estimated annual attack rates ranged from 13% in 2013 to 42% in 2005. 374 There is large uncertainty in estimated influenza attack rates. Recent estimates ranged 375 from 3-11% *symptomatic* infections among vaccinated and unvaccinated US residents 376 during 2010-2016 (56) to 32% confirmed infection among unvaccinated individuals during 377 2015 in New Zealand (57). In comparison, our estimates for Hong Kong are relatively high 378 but plausible given the longer epidemic duration and lower vaccination rates in Hong Kong 379 $(\sim 10\% (58, 59) \text{ v}. \sim 45\% \text{ in the US (60)})$. It could also be due to overestimation of A(H3N2) 380 incidence rates, as patients infected with A(H3N2) may be more likely to seek treatment 381 due to more severe symptoms compared to A(H1N1) and B. Further, while we calibrated the incidence rates of A(H1N1) during the 2009 pandemic to the estimated attack rate from 382 383 serological data (see Methods), our model-inference system did not include public health 384 interventions implemented particularly at the beginning of the pandemic. As a result, our model-inference system—entirely based on incidence data—likely underestimated the 385 386 increase in susceptibility at the onset of the pandemic. Nevertheless, the estimated timing 387 of antigenic innovations (6 July 2019) was very close to the observed onset of the pandemic

in Hong Kong (30 June 2019 (61)). Finally, due to a lack of age-specific incidence data and
for simplicity, we did not include age structure in our model. Recent studies have reported
differences in immune imprinting in children compared to adults (47, 48). Future work
may investigate such age differences further should age-specific incidence data become
available.

393

394 In summary, using a comprehensive model-inference system, we have revealed in 395 great detail the epidemiological interactions among the three influenza types/subtypes, the 396 antigenic innovations for each type/subtype, and their combined impact on the 397 transmission dynamics of influenza over the last two decades in Hong Kong, a city of global 398 public health significance for influenza epidemic and pandemic control. The intricate 399 epidemiological interactions among influenza viruses and key underlying population 400 features underscore the importance of monitoring population immunity to different 401 influenza viruses, incidence rates, and viral genetic and antigenic changes. Meanwhile, the 402 model-inference system developed here has proven powerful for estimating key 403 evolutionary and epidemiological characteristics of influenza viruses based on 404 type/subtype-specific incidence data and could be extended to study influenza epidemic 405 dynamics in other regions with limited antigenic data.

406

407 Materials and Methods

408 Influenza surveillance data. The Centre for Health Protection in Hong Kong monitors
409 seasonal influenza activity through a sentinel surveillance network of approximately 50
410 private-sector outpatient clinics that report weekly proportion of outpatients presenting

411 with influenza-like illness (ILI; defined as fever >38.0°C plus cough and/or sore throat) (62-64). In addition, the Public Health Laboratory Services Branch thereof conducts 412 413 laboratory testing for influenza viruses in samples submitted mainly from local hospitals 414 and also a small number of samples submitted by the sentinel outpatient physicians. We 415 obtained weekly records of ILI consultation rate and concurrent (sub)type-specific influenza detection rate from the week ending 04 Jan 1998 to the week ending 14 July 416 417 2018. To obtain a more specific measure of the incidence of influenza virus infections in the 418 community, we multiplied the weekly ILI rate by the concurrent viral isolation rate for 419 A(H1N1), A(H3N2) and B, respectively (42, 49, 65, 66). We refer to these combined 420 measures as A(H1N1)+, A(H3N2)+, and B+.

421

422 *Converting ILI consultation rate to infection rate*

The ILI consultation rate is the ratio of patients presenting ILI to all patient-visits and does not measure true influenza incidence rate in the catchment population. Previously, we showed that conversion to *per-capita* infection rate can be made based on Bayes' rule (65, 67). Briefly, ILI+ (here, ILI+ = A(H1N1)+, A(H3N2)+, or B+) estimates the probability that a person seeking medical attention, *m*, has influenza, i.e., p(i|m). By Bayes' rule, the incidence rate, or probability of a person contracting influenza during a given week, p(i), is:

429
$$p(i) = \frac{p(m)}{p(m|i)} ILI,$$

430 This formula can thus convert ILI+ to the incidence rate p(i) if $\gamma = \frac{p(m)}{p(m|i)}$ is known. 431 In our previous work, we estimated the conversion factor γ along with other model state

432 variables and parameters using a model-inference system without strain-interactions (36).

Here to reduce model uncertainty and complexity, we estimated γ separately based on 433 434 independent estimates of attack rate during the pandemic. Based on serological data, 435 estimated attack rates for the 2009 pandemic ranged from 16% (68) to \sim 20% (61, 69). 436 Using the upper end of these estimates and the cumulative pandemic H1N1+ rate over the 437 same time period (i.e., 42%), the conversion factor γ is ~0.5 for the pandemic. For the inter-438 pandemic period, we set γ =1, which resulted in annual attack rates ranging from 13% in 439 2013 and 42% in 2005. The attack rate in 2005 was the highest due to epidemics of all three types/subtypes in the same year (3.3%, 31.1%, and 7.4% attack rates for A(H1N1), 440 441 A(H3N2), and B, respectively). These estimates are higher than temperate regions but 442 plausible given the year-round circulation of influenza and low vaccination rates in Hong 443 Kong.

444

445 **Estimating the empirical seasonal cycle of influenza epidemic.** As discussed in the 446 Introduction, the seasonality of influenza epidemics in Hong Kong is weaker than in 447 temperate locations. To model this seasonality, we first computed the weekly average of 448 incidence rate over the study period, excluding year 2009 during which seasonality may be 449 altered due to the A(H1N1) pandemic. We then estimated the time-varying R_0 for each week of the year using a model-inference system we previously developed for Hong Kong 450 451 (36). This system used a basic Susceptible-Infectious-Recovered (SIR) model and ran it 452 with a particle filter with space re-probing. We further smoothed the posterior estimates of R_0 using 3-week moving average and used these estimates as the prior in the multi-strain 453 454 SIRS model-inference system (described below) to represent the empirical seasonal cycle. 455

456 **Multi-strain SIRS model.** A number of mathematical models have been developed (19-29. 70-73) to study the interplay of influenza viruses. The central idea behind these models is 457 458 that cross-immunity can either reduce the chance of reinfection and transmission in any 459 individual with prior infection by a similar strain (i.e. leaky immunity) or protect a portion 460 of individuals with prior infection (i.e. polarized immunity). In particular, Gog and Grenfell 461 (24) developed a parsimonious status based multi-strain model by assuming polarized 462 immunity and cross-immunity acted to reduce transmission risk. This model is able to 463 generate evolutionary dynamics similar to that observed for influenza and is commonly 464 used as the backbone for more complex phylodynamic models (26, 28, 73, 74). The multi-465 strain SIRS model in this study took a construct similar to the Gog & Grenfell model:

$$\begin{cases} \frac{dS_i}{dt} = -\sum_j \frac{c_{ij}\beta_j S_j I_j}{N} + \frac{N - S_i - I_i}{L_i} + \mu(N - S_i) - \alpha \\ \frac{dI_i}{dt} = \frac{\beta_i S_i I_i}{N} - \frac{I_i}{D_i} - \mu I_i + \alpha \end{cases}$$
[1]

466

where N is the population size; S_i and I_i , are, respectively, the numbers susceptible and 467 468 infected, to virus-*i* (here A(H1N1), A(H3N2), or B); β_i , D_i , and L_i are, respectively, the 469 transmission rate, mean infectious period, and mean immunity period, for virus-*i*; and *c_{ii}* 470 measures the strength of cross-immunity to virus-*i* conferred by infection of virus-*j* (e.g., 471 close to 0 if it is weak and $c_{ii}=1$ for strain-specific immunity). We assumed the total 472 population size is stable over the study period such that the birth rate and death rate are 473 equal and both are represented by parameter μ . The parameter α represents travel-related 474 importation of cases and for simplicity was set to 0.1 per 100,000 per day throughout the 475 study period. The model was run continuously in daily time-step from 1 Jan 1998 to 14 July

2018 in conjunction with the SR-IF2 filter (described below), during which
variables/parameters were updated weekly at the arrival of observations.

478

479 Inference on transmission dynamics using the SR-IF2 algorithm. We applied a 480 modified IF2 algorithm (termed SR-IF2) to estimate the model state variables and 481 parameters for each week in the 20-year study period. The original IF2 algorithm, 482 developed by and described in detail in Ionides et al (41, 75), implements an iterated, 483 perturbed Bayes map for inference of partially observed dynamic systems. In each 484 iteration, it uses a particle filter (34) to estimate the likelihood of the observed time series 485 (here the A(H1N1)+, A(H3N2)+, and B+ time series altogether). The particle filter uses a 486 suite of model replicates, each is initially randomly drawn from the prior, to represent 487 samples of the latent dynamic variables. Over the course of filtering, the particles are 488 numerically integrated forward in time per the dynamic model (here the multi-strain 489 model in Eqn 1) and resampled based on the likelihood to update the distribution of all 490 model parameters/variables per Bayes' rule at each time step (here each week). At the end 491 of the time series, model parameters are recycled as starting parameters for the next 492 iteration. In theory, this procedure converges to the maximum likelihood estimate.

493

While the original IF2 incorporates perturbations of model parameters, our
preliminary tests showed that these perturbations alone are insufficient to capture the
unexpected surges in population susceptibility due to potential punctuated antigenic
changes in the influenza virus. To tackle this issue, we further incorporated space reprobing (SR) in the IF2. Briefly, the SR step allows a small fraction (here 1%) of the model

499 ensemble to sample from the full prior range for key model variables/parameters (here, 500 the susceptibility), whenever filter divergence is detected (i.e., the likelihood drops below a 501 threshold); in addition, to capture other possible changes in parameters related to the virus 502 (e.g., R_0 and strength cross-immunity), we set time points requiring SR as break-points, for 503 which larger perturbations are applied to all model parameters/variables (75). 504 505 The priors for initiating the SR-IF2 were uniform distributions as follows: 506 $S_i \sim U[50\%, 90\%]$ of total population and $D_i \sim U[2, 4]$ days for i=A(H1N1), A(H3N2), or B. To 507 account for seasonality of each (sub)type, the prior of R_0 for week t of the year was drawn 508 from a uniform distribution with a range of the mean empirical estimate for that week 509 plus/minus one standard deviation. Correspondingly, the prior of transmission rate β_i for week t of the year was then computed as $R_{0,i}(t)/D_i(t)$. For the immunity period L_i , given the 510 511 wide range reported in the literature (from months to ~ 8 years (76, 77)), we tested prior 512 ranges from 1 to 9 years, divided into four 2-year segments (i.e., [1, 3], [3, 5], [5, 7], and [7, 513 9] years) for each type/subtype; this resulted in 4^3 =64 combinations for the three 514 type/subtypes. Cross-immunity has been observed for influenza strains of the same 515 subtype as well as across types/subtypes (7-15) and types (16-18); however, the strength 516 has rarely been reported. We thus tested prior ranges from 0% to 80% of the strength of 517 specific immunity, divided into two levels: [0%, 40%] (low) and [40%, 80%] (high); this resulted in 2⁶=64 combinations for 6 virus-pairs (c_{ii} , i=H1N1, H3N2, or B and $j \neq i$). To 518 519 reduce the number of combinations, *a priori*, we further assumed that heterotypic cross-520 immunity is low especially when the immunity period (L_i) is long; thus, for L_i >5 years, we 521 only included combinations with low A(H1N1) (or H3N2) and B interactions. Note,

522	however, with perturbations in the IF2 procedure, the posterior estimates can go outside
523	the prior range. Together, we tested a total of 736 combinations of L_i and c_{ij} priors in the
524	first round of search. We then selected the top $\sim 1\%$ runs with the best model-fits (highest
525	likelihood and fewest space re-probing needed) used their posterior estimates to compute
526	the prior range for subsequent round of search. We repeated this process until the
527	parameters converge. It took two rounds for the synthetic data and three rounds for the
528	observed data.
529	
530	For each SR-IF2 model-inference run, we performed 50 iterations of filtering with
531	5000 particles. Each run took round 8 to 10 hours to complete on a high-performance
532	cluster (https://www.mailman.columbia.edu/information-for/information-
533	technology/high-performance-computing-hpc). To account for stochasticity in model
534	initiation, we performed 5 runs for each prior in the first round and 50 runs in the second
535	and third round (i.e., final round for the observed data). From the final round, we selected
536	\sim 10 runs with the best model-fits (highest likelihood <i>and</i> fewest space re-probing needed)
537	and computed the posterior estimates across those runs per Rubin's rule (78, 79).

538

Estimating the timing and frequency of punctuated antigenic change. To identify
potential punctuated antigenic changes for each (sub)type, we computed the changes in
susceptibility for each week and considered weeks with a relative *increase* of 15% due to
punctuated antigenic changes. We also tested a cutoff of 10%, for which the identified
weeks were the same except for 2 additional weeks for A(H3N2) (1/10/1998 and

544	6/13/1999) and 1 for B ($1/28/2001$); these additional weeks were all in the early phase of
545	the study period and thus likely due to greater uncertainty in the model-inference system.
546	
547	To estimate the mean time interval between punctuated antigenic changes, we
548	computed the time intervals between subsequent antigenic changes (right censored for the
549	last observation) and fitted these to four survival models (i.e., the exponential, Weibull,
550	gamma, and log-normal distribution) using the 'flexsurv' package (80) in R
551	(https://www.r-project.org). We selected the best model estimate based on the Akaike
552	Information Criterion (AIC).
553	
554	Acknowledgements:
555	We thank the Hong Kong Center for Health Protection for providing data on sentinel
556	surveillance and laboratory surveillance for influenza. We also thank Columbia University
557	Mailman School of Public Health for access to high performance computing. Funding: WY
558	was supported by the NIH (1R03AI135926-01A1 and ES009089). EHYL and BJC were
559	supported by the Theme-based Research Scheme project no. T11-705/14N from the
560	University Grants Committee of the Hong Kong Government, and the National Institute of
561	General Medical Sciences (grant U54 GM088558 to the Harvard Center for Communicable
562	Disease Dynamics). Author contributions: Study conception (WY and BJC), model
563	development and implementation (WY), data curation (EHYL and BJC), result
564	interpretation (WY, EHYL, and BJC), first draft (WY), review and editing (WY, EHYL, and
565	BJC).
566	Competing interests: BJC reports receipt of honoraria from Roche and Sanofi. The authors

567 declare that they have no other potential competing interests.

568

569 **References:**

- 570 1. World Health Organization Influenza (Seasonal), Fact Sheet. Available at
- 571 http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed Jan 10, 2017
- 572 2. Iuliano AD, *et al.* (2018) Estimates of global seasonal influenza-associated respiratory
- 573 mortality: a modelling study. *Lancet* 391(10127):1285-1300.
- 574 3. Medina RA & Garcia-Sastre A (2011) Influenza A viruses: new research developments.
- 575 *Nature reviews. Microbiology* 9(8):590-603.
- 576 4. Bedford T, *et al.* (2014) Integrating influenza antigenic dynamics with molecular
- 577 evolution. *Elife* 3:e01914.
- 578 5. Bahl J, *et al.* (2011) Temporally structured metapopulation dynamics and persistence

of influenza A H3N2 virus in humans. *Proc Natl Acad Sci U S A* 108(48):19359-19364.

- 580 6. Smith DJ, *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus.
 581 *Science* 305(5682):371-376.
- 582 7. Pica N & Palese P (2013) Toward a universal influenza virus vaccine: prospects and
 583 challenges. *Annu Rev Med* 64:189-202.
- 584 8. Bodewes R, *et al.* (2011) Vaccination against seasonal influenza A/H3N2 virus reduces
- 585 the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in
- 586 ferrets. J. Virol. 85(6):2695-2702.
- 587 9. Ekiert DC, *et al.* (2009) Antibody recognition of a highly conserved influenza virus
 588 epitope. *Science* 324(5924):246-251.

- 589 10. Ekiert DC, *et al.* (2011) A highly conserved neutralizing epitope on group 2 influenza A
 590 viruses. *Science* 333(6044):843-850.
- 591 11. Epstein SL (2006) Prior H1N1 Influenza Infection and Susceptibility of Cleveland
- 592 Family Study Participants during the H2N2 Pandemic of 1957: An Experiment of
- 593 Nature. J. Infect. Dis. 193(1):49-53.
- 594 12. McMichael AJ, Gotch FM, Noble GR, & Beare PA (1983) Cytotoxic T-cell immunity to
 595 influenza. *N. Engl. J. Med.* 309(1):13-17.
- 596 13. Miller MS, et al. (2012) 1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-
- Hemagglutinin Stalk Antibodies in Humans. J. Infect. Dis. 207(1):98-105.
- 598 14. Sandbulte MR, et al. (2007) Cross-reactive neuraminidase antibodies afford partial
- protection against H5N1 in mice and are present in unexposed humans. *PLoS Med*4(2):e59.
- 601 15. Katz J, et al. (2009) Serum cross-reactive antibody response to a novel influenza A
- 602 (H1N1) virus after vaccination with seasonal influenza vaccine. *MMWR. Morb. Mortal.*603 *Wkly. Rep.* 58(19):521-524.
- 604 16. Dreyfus C, *et al.* (2012) Highly Conserved Protective Epitopes on Influenza B Viruses.
 605 *Science* 337(6100):1343-1348.
- 606 17. Stanekova Z & Vareckova E (2010) Conserved epitopes of influenza A virus inducing
- 607 protective immunity and their prospects for universal vaccine development. *Virol J*608 7:351.
- 609 18. Laurie K, *et al.* (2016) The time-interval between infections and viral hierarchies are
- 610 determinants of viral interference following influenza virus infection in a ferret model.
- *Eur J Immunol* 46:685-686.

- 612 19. Andreasen V (2003) Dynamics of annual influenza A epidemics with immuno-selection.
- 613 *Journal of mathematical biology* 46(6):504-536.
- 614 20. Bansal S & Meyers LA (2012) The impact of past epidemics on future disease dynamics.
- *Journal of theoretical biology* 309:176-184.
- 616 21. Boni MF, Gog JR, Andreasen V, & Christiansen FB (2004) Influenza drift and epidemic
- 617 size: the race between generating and escaping immunity. *Theor Popul Biol* 65(2):179-
- 618 191.
- 619 22. Casagrandi R, Bolzoni L, Levin SA, & Andreasen V (2006) The SIRC model and influenza
- 620 A. *Mathematical Biosciences* 200(2):152-169.
- 621 23. Chung KW & Lui R (2016) Dynamics of two-strain influenza model with cross-
- 622 immunity and no quarantine class. *Journal of mathematical biology* 73(6-7):1467-1489.
- 623 24. Gog JR & Grenfell BT (2002) Dynamics and selection of many-strain pathogens. *Proc*
- 624 *Natl Acad Sci U S A* 99(26):17209-17214.
- 625 25. Gog JR & Swinton J (2002) A status-based approach to multiple strain dynamics.
- *Journal of mathematical biology* 44(2):169-184.
- 627 26. Koelle K, Cobey S, Grenfell B, & Pascual M (2006) Epochal evolution shapes the
- 628 phylodynamics of interpandemic influenza A (H3N2) in humans. *Science*
- **629 314(5807):1898-1903**.
- 630 27. Koelle K & Rasmussen DA (2015) The effects of a deleterious mutation load on patterns
- of influenza A/H3N2's antigenic evolution in humans. *Elife* 4:e07361.
- 632 28. Kucharski A & Gog JR (2012) Influenza emergence in the face of evolutionary
- 633 constraints. *Proc. R. Soc. B-Biol. Sci.* 279(1729):645-652.

634	29. N	Minavev	P & Fei	rguson N	(2009)) Incor	porating	demos	grat	phic sto	chastici	tv inte	o multi-
001		in a jet	1 0 1 0	Babonit		,	o o i a cimp	aomoş	<u>, , , , , , , , , , , , , , , , , , , </u>		cinaberei	<i>cy</i> 111 <i>c</i> ,	o manei

- 635 strain epidemic models: application to influenza A. *Journal of the Royal Society Interface*
- 636 6(40):989-996.
- 637 30. Magal P & Ruan SG (2010) Sustained oscillations in an evolutionary epidemiological
- 638 model of influenza A drift. *P R Soc A* 466(2116):965-992.
- 639 31. Nuno M, Chowell G, Wang X, & Castillo-Chavez C (2007) On the role of cross-immunity
- and vaccines on the survival of less fit flu-strains. *Theor Popul Biol* 71(1):20-29.
- 641 32. Wu P, et al. (2017) A joint analysis of influenza-associated hospitalizations and
- 642 mortality in Hong Kong, 1998-2013. *Sci Rep* 7(1):929.
- 643 33. Feng S, et al. (2018) Effectiveness of influenza vaccination on influenza-associated
- hospitalisations over time among children in Hong Kong: a test-negative case-control
 study. *Lancet Resp Med* 6(12):925-934.
- 646 34. Arulampalam MS, Maskell S, Gordon N, & Clapp T (2002) A tutorial on particle filters
- 647 for online nonlinear/non-Gaussian Bayesian tracking. *IEEE Trans. Signal Process.*648 50(2):174-188.
- 649 35. van Leeuwen PJ (2009) Particle Filtering in Geophysical Systems. *Mon. Weather Rev.*650 137(12):4089-4114.
- 36. Yang W, Cowling BJ, Lau EH, & Shaman J (2015) Forecasting Influenza Epidemics in
 Hong Kong. *PLoS Comput Biol* 11(7):e1004383.
- 653 37. Shaman J, Pitzer VE, Viboud C, Grenfell BT, & Lipsitch M (2010) Absolute humidity and
- the seasonal onset of influenza in the continental United States. *Plos Biol*
- 655 8(2):e1000316.

656	38. Axelsen	B, Yaari R, Grenf	ell BT, & Stone L (2014	 Multiannual forecasting of seasona 	ıl
-----	-------------	-------------------	-------------------------	--	----

- 657 influenza dynamics reveals climatic and evolutionary drivers. *Proc Natl Acad Sci U S A*
- **658** 111(26):9538-9542.
- 659 39. Ionides EL, Bhadra A, Atchade Y, & King A (2011) Iterated filtering. *Ann. Stat.*
- 660 39(3):1776-1802.
- 40. Ionides EL, Breto C, & King AA (2006) Inference for nonlinear dynamical systems. *Proc Natl Acad Sci U S A* 103(49):18438-18443.
- 41. Ionides EL, Nguyen D, Atchade Y, Stoev S, & King AA (2015) Inference for dynamic and
- latent variable models via iterated, perturbed Bayes maps. *Proc Natl Acad Sci U S A*
- 665 112(3):719-724.
- 42. Yang W, Karspeck A, & Shaman J (2014) Comparison of filtering methods for the
- 667 modeling and retrospective forecasting of influenza epidemics. *PLoS Comput Biol*
- 668 10(4):e1003583.
- 43. Yang W & Shaman J (2014) A simple modification for improving inference of non-linear
 dynamical systems. *arXiv*:1403.6804.
- 44. Wu JT, *et al.* (2010) School closure and mitigation of pandemic (H1N1) 2009, Hong
 Kong. *Emerging infectious diseases* 16(3):538-541.
- 45. Liao Q, Cowling B, Lam WT, Ng MW, & Fielding R (2010) Situational awareness and
- health protective responses to pandemic influenza A (H1N1) in Hong Kong: a cross-
- 675 sectional study. *Plos One* 5(10):e13350.
- 46. Boelle PY, Ansart S, Cori A, & Valleron AJ (2011) Transmission parameters of the
- 677 A/H1N1 (2009) influenza virus pandemic: a review. *Influenza Other Respir Viruses*
- **678 5(5):306-316**.

- 47. Ranjeva S, *et al.* (2019) Age-specific differences in the dynamics of protective immunity
 to influenza. *Nat Commun* 10(1):1660.
- 48. Kucharski AJ, *et al.* (2015) Estimating the life course of influenza A(H3N2) antibody
- responses from cross-sectional data. *Plos Biol* 13(3):e1002082.
- 49. Goldstein E, Cobey S, Takahashi S, Miller JC, & Lipsitch M (2011) Predicting the
- 684 epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. *PLoS Med*
- 685 8(7):e1001051.
- 50. Smith DJ, *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus.
- 687 *Science* 305(5682):371-376.
- 688 51. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, & Finelli L (2014) Estimates of the
- reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic
 review of the literature. *Bmc Infect Dis* 14:480.
- 691 52. Carrat F, *et al.* (2008) Time lines of infection and disease in human influenza: a review
 692 of volunteer challenge studies. *Am J Epidemiol* 167(7):775-785.
- 693 53. Cowling BJ, *et al.* (2014) Incidence of influenza virus infections in children in Hong
- 694 Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012. *Clinical*
- 695 infectious diseases : an official publication of the Infectious Diseases Society of America
 696 59(4):517-524.
- 697 54. Budd AP, *et al.* (2019) Birth Cohort Effects in Influenza Surveillance Data: Evidence
- 698 That First Influenza Infection Affects Later Influenza-Associated Illness. *The Journal of*
- 699 *infectious diseases* 220(5):820-829.

700	55. NextStrain.org Real-time tracking of influenza A/H1N1pdm evolution. Available at
701	https://nextstrain.org/flu/seasonal/h1n1pdm/ha/12y?c=cTiter&f_country=hong_kon
702	g Accessed
703	56. Tokars JI, Olsen SJ, & Reed C (2018) Seasonal Incidence of Symptomatic Influenza in the
704	United States. Clinical Infectious Diseases 66(10):1511-1518.
705	57. Huang QS, et al. (2019) Risk Factors and Attack Rates of Seasonal Influenza Infection:
706	Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and
707	Surveillance (SHIVERS) Seroepidemiologic Cohort Study. Journal of Infectious Diseases
708	219(3):347-357.
709	58. Lee SS, Leung EH, & Wong NS (2013) Concerns for low coverage of influenza
710	vaccination in middle-aged adults. Human vaccines & immunotherapeutics 9(9):1989-
711	1990.
712	59. Centre for Health, Protection Department of Health, & The Govenment of the Hong
713	Kong Special Administrative Region Statistics on 2016/17 Vaccination
714	Programmes/Schemes Available at
715	http://www.chp.gov.hk/en/view_content/26734.html Accessed
716	60. Centers for Disease Control and Prevention National Early-Season Flu Vaccination
717	Coverage, United States, November 2016. Available at
718	https://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2016.htm Accessed
719	61. Wu JT, et al. (2014) Inferring influenza infection attack rate from seroprevalence data.
720	<i>PLoS Pathog</i> 10(4):e1004054.

721 62. Lau EHY, Cheng CKY, Ip I	p DKM. & Cowling BI (201)	?) Situational Awareness of Influenza
----------------------------------	---------------------------	---------------------------------------

Activity Based on Multiple Streams of Surveillance Data Using Multivariate Dynamic

723 Linear Model. *Plos One* 7(5):e38346.

- 63. Lau EHY, Cowling BJ, Ho LM, & Leung GM (2008) Optimizing use of multistream
- influenza sentinel surveillance data. *Emerging infectious diseases* 14(7):1154-1157.
- 64. Cowling BJ, Wong IO, Ho LM, Riley S, & Leung GM (2006) Methods for monitoring
- influenza surveillance data. *International journal of epidemiology* 35(5):1314-1321.
- 65. Shaman J, Karspeck A, Yang W, Tamerius J, & Lipsitch M (2013) Real-time influenza
- forecasts during the 2012-2013 season. *Nat Commun* 4:2837.
- 66. Wong JY, *et al.* (2013) Infection fatality risk of the pandemic A(H1N1)2009 virus in
- 731 Hong Kong. *Am J Epidemiol* 177(8):834-840.
- 732 67. Yang W, Lipsitch M, & Shaman J (2015) Inference of seasonal and pandemic influenza
 733 transmission dynamics. *Proc Natl Acad Sci U S A* 112(9):2723-2728.
- 68. Riley S, et al. (2011) Epidemiological characteristics of 2009 (H1N1) pandemic
- influenza based on paired sera from a longitudinal community cohort study. *PLoS Med*8(6):e1000442.
- 737 69. Tsang TK, *et al.* (2016) Interpreting Seroepidemiologic Studies of Influenza in a Context
 738 of Nonbracketing Sera. *Epidemiology (Cambridge, Mass.)* 27(1):152-158.
- 739 70. Bhattacharyya S, Gesteland PH, Korgenski K, Bjornstad ON, & Adler FR (2015) Cross-
- immunity between strains explains the dynamical pattern of paramyxoviruses. *Proc*

741 *Natl Acad Sci USA* 112(43):13396-13400.

- 742 71. Gog JR (2008) The impact of evolutionary constraints on influenza dynamics. *Vaccine*
- 743 26:C15-C24.

744	72. Nuño M, Feng Z, Martcheva M, & Castillo-Chavez C (2005) Dynamics of Two-Strain
745	Influenza with Isolation and Partial Cross-Immunity. SIAM Journal on Applied
746	Mathematics 65(3):964-982.
747	73. Koelle K, Khatri P, Kamradt M, & Kepler TB (2010) A two-tiered model for simulating
748	the ecological and evolutionary dynamics of rapidly evolving viruses, with an
749	application to influenza. Journal of the Royal Society Interface 7(50):1257-1274.
750	74. Arinaminpathy N, et al. (2012) Impact of cross-protective vaccines on epidemiological
751	and evolutionary dynamics of influenza. <i>Proc Natl Acad Sci USA</i> 109(8):3173-3177.
752	75. Inoue E & King A Iterated filtering: principles and practice. Available at
753	https://kingaa.github.io/sbied/mif/mif.html Accessed
754	76. Ferguson NM, Galvani AP, & Bush RM (2003) Ecological and immunological
755	determinants of influenza evolution. <i>Nature</i> 422(6930):428-433.
756	77. Yaari R, Katriel G, Huppert A, Axelsen JB, & Stone L (2013) Modelling seasonal
757	influenza: the role of weather and punctuated antigenic drift. J R Soc Interface
758	10(84):20130298.
759	78. Marshall A, Altman DG, Holder RL, & Royston P (2009) Combining estimates of interest
760	in prognostic modelling studies after multiple imputation: current practice and
761	guidelines. BMC Med Res Methodol 9:57.
762	79. Rubin DB (2004) Multiple imputation for nonresponse in surveys (John Wiley & Sons).
763	80. Jackson CH (2016) flexsurv: a platform for parametric survival modeling in R. Journal
764	of Statistical Software 70.

Table Captions:

Table 1. Estimates of key parameters. Posterior estimates from all runs and weeks are pooled to obtain the mean and full range (in parentheses).

Table 2. Estimated timing and frequency of potential punctuated antigenic changes. Dates (mm/dd/yy) of potential punctuated antigenic changes are identified based on above 15% increases in susceptibility; the standard deviations are computed based on estimates from all model-inference runs indicating punctuated antigenic changes around the same time. The time intervals between subsequent antigenic changes are estimated based on four different distributions; the best-fit estimates are shown in bold. For A(H1N1), numbers in the parentheses show results when dates during the pandemic are included.

Figure Captions:

Fig. 1. Seasonality of influenza epidemics in Hong Kong. Upper panel: annual cycles for A(H1N1) (A), A(H3N2) (B), and B (C). Color lines show infection rates for individuals years during Jan 1998 –July 2018; lighter colors show earlier years and darker colors for later years. Thick black lines show the mean excluding 2009 for the A(H1N1) pandemic. Lower panel: estimated seasonal R_0 cycles for A(H1N1) (D), A(H3N2) (E), and B (F).

Fig. 2. Estimates of weekly infection rate and population susceptibility for the three types/subtypes: A(H1N1) (A), A(H3N2) (B) and B (C). Black dots show observed incidence rates (left y-axis); the lines run through the dots show model estimates; surrounding grey areas show the 95% credible intervals (CI). Blue lines and surrounding areas show the mean and 95% CI estimates of the population susceptibility. Vertical red lines and dates show identified timing of punctuated antigenic changes.

Fig. 3. Estimates of weekly reproductive number: basic reproductive number (A) and effective reproductive number (B). Blue lines and areas show the mean and 95% CI estimates. For comparison, the observed (black dots) and estimated (black lines) incidence rates are superimposed (right y-axis).

Supplementary Material Captions: Supplemental testing and results.

Table S1. Estimated timing of punctuated antigenic changes using a cutoff of 10% increase in susceptibility, instead of 15% in Table 2.

Fig. S1. Example model fits and estimates of key parameters using a particle filter. Model fits compared to the observations are shown for A(H1N1) (A), A(H3N2) (B), and B (C). Estimates of R_0 are shown in D-F for the three influenza types/subtypes and strength of cross-immunity shown in G-L.

Fig. S2. Model validation using the first synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared

to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with punctuated antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.

Fig. S3. Model validation using the second synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with punctuated antigenic changes and red lines show modelestimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.

Fig. S4. Epidemics for individual types/subtypes as defined by the criteria including small epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.

Fig. S5. Epidemics for individual types/subtypes as defined by the criteria including only large epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.

Fig. S6. Distributions of residuals of incidence rate estimates. Numbers below the name of virus show the mean and 95% confidence interval in parentheses.

Fig. S7. Weekly estimates of key model parameters: infectious period for A(H1N1) (A), A(H3N2) (B), and B (C); immunity period for A(H1N1) (D), A(H3N2) (E), and B (F); and strength of cross-immunity for the six virus-pairs (G-L). Solid lines and surrounding areas show the posterior mean and 95% CI estimates and dashed lines show the prior ranges.

Fig. S8. Simulations using the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S9. Simulations assuming stronger cross-immunity from A(H3N2) against A(H1N1). The cross-immunity parameter $c_{H1 \leftarrow H3}$ was set to 0.5 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000

individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S10. Simulations assuming no cross-immunity. All cross-immunity terms were set to 0 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S11. Epidemic and co-circulation patterns under different strengths of cross-immunity. Box and whisker plots show the distributions across 1000 simulations for each cross-immunity scenario: scenario 1 as estimated in green; scenario 2 with stronger cross-immunity from A(H3N2) against A(H1N1) in orange; and scenario 3 with no cross-immunity in grey. Horizontal thick black lines show the median; box edges show the 25th and 75th percentiles; the whiskers show the full ranges and dots show outliers. Red segments show the corresponding observations in Hong Kong.

Tables:

Table 1. Estimates of key parameters. Posterior estimates from all runs and weeks are pooled to obtain the mean and full range (in parentheses).


	Strength of cross	-immunity (c _{ij})			Infectious period	Immunity period
Strain	A(H1N1)	A(H3N2)	В	Ro	(days)	(years)
A(H1N1)		0.17 (0.11, 0.23)	0.32 (0.26, 0.4)	1.44 (1.07, 1.82)	2.64 (2.15, 3.76)	3.12 (2.64, 3.98)
A(H3N2)	0.4 (0.23, 0.56)		0.24 (0.16, 0.31)	1.60 (1.32, 1.99)	3.03 (2.57, 4.30)	2.28 (1.77, 2.59)
В	0.23 (0.19, 0.32)	0.11 (0.06, 0.17)		1.43 (1.13, 1.79)	3.09 (2.15, 4.06)	3.08 (2.73, 3.48)

Table 2. Estimated timing and frequency of potential punctuated antigenic changes. Dates (mm/dd/yy) of potential punctuated antigenic changes are identified based on above 15% increases in susceptibility; the standard deviations are computed based on estimates from all model-inference runs indicating punctuated antigenic changes around the same time. The time intervals between subsequent antigenic changes are estimated based on four different distributions; the best-fit estimates are shown in bold. For A(H1N1), numbers in the parentheses show results when dates during the pandemic are included.

	Timing of change		Time intervals between antigenic changes			
			Mean			
Strain	Date	SD (days)	(years)	SD (years)	Distribution	AIC
A(H1N1)	1/21/00	4.2	4.6 (3.7)	4.6 (3.7)	exponential	69.45
	6/11/06	0	2.9 (2.0)	0.01 (0.01)	log-norm	70.62
	1/25/09	0	4.5 (3.8)	4.1 (4.2)	gamma	71.35
	7/6/09	3.5	4.5 (3.9)	4.2 (4.7)	Weibull	71.42
	9/13/09	2.2				
	1/5/10	4				
	1/14/11	2.6				
	•					166.2
A(H3N2)	5/15/98	6.2	1.8	1.2	gamma	6
	1/10/99	4.2	1.8	1.1	Weibull	166.29
	1/9/00	1.9	1.4	0.01	log-norm	166.31
	6/27/00	6.3	1.8	1.8	exponential	167.15
	1/14/03	8.8				
	7/11/04	0				
	2/27/05	14.8				
	6/20/07	3.7				
	7/28/10	4				
	5/10/12	8.1				
	1/3/15	3.7				
	6/8/15	5.7				
В	2/6/00	0	6.2	6.2	exponential	54.30
	1/27/02	0	3.2	0.01	log-norm	55.64
	1/6/03	7.2	6.2	6.7	Weibull	56.26
	1/13/18	0	6.2	6.4	gamma	56.29


1 Figures:

- 2 **Fig. 1.** Seasonality of influenza epidemics in Hong Kong. Upper panel: annual cycles for
- 3 A(H1N1) (A), A(H3N2) (B), and B (C). Color lines show infection rates for individuals years
- 4 during Jan 1998 July 2018; lighter colors show earlier years and darker colors for later
- 5 years. Thick black lines show the mean excluding 2009 for the A(H1N1) pandemic. Lower
- 6 panel: estimated seasonal R_0 cycles for A(H1N1) (D), A(H3N2) (E), and B (F).




7 8 9

- 10 **Fig. 2.** Estimates of weekly infection rate and population susceptibility for the three
- 11 types/subtypes: A(H1N1) (A), A(H3N2) (B) and B (C). Black dots show observed incidence
- 12 rates (left y-axis); the lines run through the dots show model estimates; surrounding grey
- 13 areas show the 95% credible intervals (CI). Blue lines and surrounding areas show the
- 14 mean and 95% CI estimates of the population susceptibility. Vertical red lines and dates
- 15 show identified timing of punctuated antigenic changes.



16

- 17 **Fig. 3.** Estimates of weekly reproductive number: basic reproductive number (A) and
- 18 effective reproductive number (B). Blue lines and areas show the mean and 95% CI
- 19 estimates. For comparison, the observed (black dots) and estimated (black lines) incidence
- 20 rates are superimposed (right y-axis).



1	SI Appendix
2	Dynamic interactions of influenza viruses in Hong Kong during 1998-2018
3	Wan Yang, Eric H. Y. Lau, Benjamin J. Cowling
4	
5	This supplemental document includes 1) Validation of the model-inference system using
6	model-generated mock epidemics; 2) Simulations to test the impact of cross-immunity on
7	long-term epidemic pattern; and supplemental table and figures.
8	
9	1. Validation of the model-inference system
10	1.1 Method
11	We first tested our multi-strain SIRS model-SR-IF2 inference system using model-
12	generated mock epidemics (i.e. synthetic data). Specifically, we tested its ability to
13	estimate three main epidemic features of interest: 1) The population susceptibility for each
14	virus over time, including timing of major susceptibility increase due to epochal antigenic
15 10	change. For the latter, we tested three levels of magnitude—small, medium, and large
16 17	change—with 10%, 15%, and 25% increase in susceptibility, respectively. 2) The strength
17 18	of cross-immunity between each virus-pair. For this, we tested two combinations of heterosubtypic immunity (i.e., low H3N2→H1N1 and high H1N1→H3N2 cross-immunity for
18 19	the first synthetic dataset; high H3N2 \rightarrow H1N1 and median H1N1 \rightarrow H3N2 cross-immunity for
20	the second). and 3) The duration of immunity. Reported immunity period for influenza
21	varied substantially, ranging from months to ~8 years (1-4). Thus, we tested prior ranges
22	from 1 to 9 years.
23	
24	To generate the mock epidemics for the above testing, we first generated 100,000
25	random combinations of initial conditions and model parameters except R_0 , using Latin
26	Hypercube sampling. Weekly R_0 values were randomly sampled from a normal distribution
27	with the mean set to the empirical estimate for that week (Fig 1 in the main text) and
28	standard deviation set to 5% of the mean. To mimic punctuated antigenic changes, for each
29	(sub)type, we first identified the observed major epidemic peak weeks (peak ILI+ in the
30	upper ~75%, 60%, and 75% percentiles for the three (sub)types, respectively); for each
31	selected peak week, we increased the susceptibility at the 8 th preceding week (i.e., roughly
32	the onset) by 15% for A(H1N1) (except for the pandemic) and A(H3N2), by 10% for B, and
33	by 25% for the A(H1N1) pandemic (see the selected weeks in Figs S2 and S3). We then ran
34	the multi-strain SIRS model (Eqn 1 in the main text) for each setting and selected 2
35	simulations that most closely resembled the observed epidemics in Hong Kong but had
36	different levels of cross-immunity between the two A subtypes: the first simulated time
37 20	series had high cross-immunity from A(H1N1) against A(H3N2) but low cross-immunity in
38	the reverse direction; and the second had moderate cross-immunity from A(H1N1) against
39	A(H3N2) and high cross-immunity from A(H3N2) against A(H1N1). We then added Poisson

40 random noise to the two simulated time series to mimic observational errors and used

- 41 these as mock data (termed synthetic 'truth') to test the model-inference system.
- 42

43 For each of the two synthetic truths, we performed two rounds of model-inference

44 using the same procedure and prior distributions for the Hong Kong dataset as described in

45 the main text. To evaluate the accuracy of the final posterior estimates, we computed the

- 46 root-mean-square-error and correlation with the 'truth'.
- 47

48 1.2 Results

- 49 Figures S2 and S3 show the posterior estimates of key model state variables (population
- 50 susceptibility for the three types/subtypes) and parameters (the basic reproductive
- 51 number R_0 , infectious period, immunity period and strength of cross-immunity) for the two
- 52 tests, respectively, compared with the true values. The relative root-mean-square-error
- 53 was 0.16 and the correlation was 0.83 combining all model variables/parameters from
- 54 both tests. These results suggest that our model-inference system and parameter
- 55 estimation strategy is able to accurately estimate the model state variables and parameters.
- However, due to large fluctuations of R_{θ} in the synthetic datasets (e.g., Fig S2B) and the
- 57 collinearity between R_0 and susceptibility, the filter tended to compensate sudden
- 58 increases in infections (due to increases in susceptibility to mimic punctuated antigenic
- 59 changes) with increases in R_0 rather than susceptibility. As a result, it failed to identify
- 60 some of the punctuated antigenic changes, in particular, for the two A subtypes with larger
- 61 variances of R_0 .
- 62

63 2. Simulating the impact of cross-immunity on long-term epidemic pattern

- 64 *2.1 Method*
- 65 To test the impact of cross-immunity, we simulated epidemics under three different
- scenarios: 1) As estimated in this study, by setting all cross-immunity terms to the
- 67 posterior mean estimates; 2) Stronger cross-immunity from A(H3N2) against A(H1N1), by
- setting $c_{H1 \leftarrow H3}$ to 0.5, i.e., slightly above the mean estimate for $c_{H3 \leftarrow H1}$ (i.e. 0.4); and 3) No
- 69 interactions, by setting all cross-immunity terms to 0. For each simulation, we initiated the
- 70 multi-strain SIRS model (Eqn 1 in the main text) using the posterior estimates at Week 4
- 71 (i.e., after discarding the first three weeks of filter spin-off) and ran the model
- stochastically from Jan 1998 to July 2018. Weekly values of model parameters (i.e., the
- infectious period, immunity period, R_0 , and cross-immunity terms) not specified in the
- above scenarios were set to the mean posterior estimates from the Hong Kong dataset.
- 75 Weekly susceptibilities to the three types/subtypes were simulated by the model according
- 76 to model-simulated infections, loss of immunity, cross-immunity, replenishment from
- 77 newborns, and deaths; however, to simulate the impact from antigenic innovations, we
- 78 reset the susceptibility to the posterior mean estimate from the Hong Kong dataset for
- 79 weeks identified to experience punctuated antigenic changes (Table 1). As in the model-

80 inference runs, we set the epidemic seeding (α in Eqn 1) to 0.1 per 100,000 per day for the 81 all simulations. To account for model stochasticity, we simulated each scenario for 1000 82 times.

83

To compute the number of epidemics over the study period, as in (5), we defined the 84 epidemic baseline, for each type/subtype, as the 40% quantile of the non-zero 85 corresponding ILI+ records over the \sim 20 year study period. We then identified 1) all 86 epidemics including small ones, defined as periods with \geq 3 consecutive weeks with ILI+ 87 88 above the baseline and at least one of the weeks with $ILI + \ge 3$ times of the baseline; and 2) 89 all large epidemics, defined as periods with ≥ 6 consecutive weeks with ILI+ above the baseline and at least one of the weeks with ILI+ ≥ 6 times of the baseline. If an identified 90 epidemic lasted for >1 year, we divided it into multiple epidemics at the year division(s). 91 Based on the 1st definition, there were 17 A(H1N1), 21 A(H3N2), and 18 B epidemics, 92 93 respectively (Fig. S4); and based on the 2nd definition, there were 13, 19, and 14 epidemics of the three types/subtypes, respectively, during Jan 1998—July 2018 (Fig. S5). We used 94 95 the same baselines as observed and definitions to identify and compute the numbers of 96 epidemics in the simulations and compared them to the observed.

97

98 To compare the co-circulation patterns, we categorized the weeks into 8 possible 99 co-circulation types: 1) none in circulation, i.e., none of the three types/subtypes had ILI+ above their baselines; 2) A(H1N1) alone, i.e., only A(H1N1) had ILI+ above its baseline; and 100 101 similarly, 3) A(H3N2) alone and 4) B alone; 5) A(H1N1)+A(H3N2), i.e., only A(H1N1) and A(H3N2) had ILI+ above their baselines; 6) A(H1N1)+B, i.e., only A(H1N1) and B had ILI+ 102 103 above their baselines; 7) A(H3N2)+B, i.e., only A(H3N2) and B had ILI+ above their 104 baselines; and 8) All, i.e., all three types/subtypes had ILI+ above their baselines. We then 105 computed the percentages of weeks falling in each of the 8 co-circulation types and compared them to the observed. 106

107

108 *2.2 Results*

109 Figures 8-10 show the model-simulated epidemic trajectories compared to the

110 observations in Hong Kong. As expected, without the constraints by observations (as in a

- 111 model-inference system), the errors grew quickly and thus the simulated epidemics
- 112 deviated from the observations. However, overall, simulations with cross-immunity in
- 113 place were able to better reproduce the observed epidemic pattern (Figs. S8 and S9 vs. Fig.
- 114 S10). In particular, those simulations were able to reproduce the long periods with near-
- zero A(H1N1) activities (e.g., 2002-2005) whereas simulations with no cross-immunity
 (Fig. S10) overestimated the circulation of all types/subtypes, especially for A(H1N1).
- (Fig. 510) overestimated the circulation of an types/subtypes, especially for A(H1N1).
- 117 Comparing the first two scenarios (i.e. both with cross-immunity), simulations with
- 118 stronger cross-immunity from A(H3N2) against A(H1N1) underestimated the circulation of
- 119 A(H1N1) and were only able to generate A(H1N1) epidemics following the simulated

punctuated antigenic changes when the susceptibility was reset (Fig. S9 vs. Fig. S8 asestimated from the data).

122

123 Tally over the entire study period, the first two scenarios (i.e., with cross-immunity) 124 appeared to underestimate the total number of the epidemics (Fig. S11 A and B). However, 125 this was due to the challenge in generating clear bimodal epidemics within a year as those observed in Hong Kong. For instance, there were two consecutive A(H1N1) epidemics in 126 127 2008; and similarly, A(H3N2) tended to cause two separate epidemics within a year, e.g., 128 1999, 2000, 2003, and 2014. The underestimation of number of A(H1N1) epidemics was 129 severer for scenario 2 when stronger cross-immunity from A(H3N2) against A(H1N1) was 130 implemented in the model. Simulations with no cross-immunity were able to generate more epidemics due to overestimation of circulation during periods without observed 131 132 influenza activity (Fig. S10).

133

Comparing the 8 co-circulation types (Fig. 11C), scenario 1 using the posterior mean estimates most closely reproduced the observed pattern. In contrast, scenario 2 (i.e.,

136 stronger cross-immunity from A(H3N2) against A(H1N1)) largely underestimated the

137 frequency of A(H1N1) epidemics, whereas scenario 3 (i.e., no cross-immunity) largely

138 overestimated co-epidemics caused by multiple types/subtypes.

139

140 References:

 Ferguson NM, Galvani AP, & Bush RM (2003) Ecological and immunological determinants of influenza evolution. *Nature* 422(6930):428-433.

- Yaari R, Katriel G, Huppert A, Axelsen JB, & Stone L (2013) Modelling seasonal
 influenza: the role of weather and punctuated antigenic drift. *J R Soc Interface* 10(84):20130298.
- 146 3. Ranjeva S, *et al.* (2019) Age-specific differences in the dynamics of protective immunity
 147 to influenza. *Nat Commun* 10(1):1660.
- Kucharski AJ, *et al.* (2015) Estimating the life course of influenza A(H3N2) antibody
 responses from cross-sectional data. *Plos Biol* 13(3):e1002082.

Yang W, Cowling BJ, Lau EH, & Shaman J (2015) Forecasting Influenza Epidemics in
 Hong Kong. *PLoS Comput Biol* 11(7):e1004383.

152

Supplementary Table

Table S1. Estimated timing of punctuated antigenic changes using a cutoff of 10% increase in susceptibility, instead of 15% in Table 2.

Strain	Date	SD (days)	
A(H1N1)	1/21/00	4.05	
	6/11/06	0.00	
	1/25/09	0.00	
	7/6/09	3.50	
	9/13/09	2.21	
	1/4/10	6.30	
	1/14/11	3.13	
A(H3N2)	1/18/98	0.00	
	5/15/98	6.19	
	1/10/99	4.31	
	6/13/99	12.12	
	1/9/00	1.94	
	6/27/00	5.72	
	1/13/03	9.46	
	7/11/04	0.00	
	2/25/05	14.53	
	6/20/07	3.74	
	7/28/10	3.83	
	5/10/12	8.08	
	1/2/15	4.21	
	6/6/15	8.08	
В	2/6/00	0.00	
	1/28/01	9.90	
	1/27/02	0.00	
	1/6/03	7.06	
	1/13/18	0.00	

Supplementary figures

Fig. S1. Example model fits and estimates of key parameters using a particle filter. Model fits compared to the observations are shown for A(H1N1) (A), A(H3N2) (B), and B (C). Estimates of R_0 are shown in D-F for the three influenza types/subtypes and strength of cross-immunity shown in G-L.




Fig. S2. Model validation using the first synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with epochal antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.




Fig. S3. Model validation using the second synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with epochal antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.




Fig. S4. Epidemics for individual types/subtypes as defined by the criteria including small epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.






Fig. S5. Epidemics for individual types/subtypes as defined by the criteria including only large epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.








Fig. S7. Weekly estimates of key model parameters: infectious period for A(H1N1) (A), A(H3N2) (B), and B (C); immunity period for A(H1N1) (D), A(H3N2) (E), and B (F); and strength of cross-immunity for the six virus-pairs (G-L). Solid lines and surrounding areas show the posterior mean and 95% CI estimates and dashed lines show the prior ranges.




Fig. S8. Simulations using the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S9. Simulations assuming stronger cross-immunity from A(H3N2) against A(H1N1). The cross-immunity parameter $c_{H1 \leftarrow H3}$ was set to 0.5 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S10. Simulations assuming no cross-immunity. All cross-immunity terms were set to 0 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S11. Epidemic and co-circulation patterns under different strengths of cross-immunity. Box and whisker plots show the distributions across 1000 simulations for each cross-immunity scenario: scenario 1 as estimated in green; scenario 2 with stronger cross-immunity from A(H3N2) against A(H1N1) in orange; and scenario 3 with no cross-immunity in grey. Horizontal thick black lines show the median; box edges show the 25th and 75th percentiles; the whiskers show the full ranges and dots show outliers. Red segments show the corresponding observations in Hong Kong.

